{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for abrocitinib in Standardized Name (approximate match)
Showing 1 - 6 of 6 results
Status:
US Approved Rx
(2022)
Source:
NDA213871
(2022)
Source URL:
First approved in 2022
Source:
NDA213871
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
PF-04965842 is an orally administered selective Janus kinase 1 (JAK1) inhibitor. PF-04965842 is currently in clinical trials for the treatment of autoimmune diseases.
